脑转移患者使用直接口服抗凝药与低分子肝素颅内出血风险比较
这项国际两中心回顾性队列研究纳入96例脑转移患者(41例DOAC,55例LMWH),比较因静脉血栓栓塞或房颤抗凝时颅内出血的累积发生率。12个月大出血累积发生率DOAC组5.1%、LMWH组11.1%(HR 0.45,95%CI 0.09-2.21);按时间变化协变量分析任何ICH风险无差异(HR 0.98,95%CI 0.28-3.40)。提示脑转移患者中DOAC与LMWH安全性相当。
要点
- 脑转移患者DOAC与LMWH的12个月大ICH累积发生率分别为5.1%和11.1%。
- 时间变化协变量分析任何ICH风险两组无差异(HR 0.98,95%CI 0.28-3.40)。
- PANWARDS评分与ICH风险无关。
核心结论
- 该国际两中心研究提示脑转移患者使用DOAC与LMWH的安全性相当。
研究设计与样本
- 国际两中心回顾性队列研究,纳入96例脑转移患者,其中41例接受DOAC、55例接受LMWH。
- 随访自抗凝与脑肿瘤诊断首日启动,要求至少2次脑影像学检查。
- 主要结局为12个月随访期间任何自发性ICH的累积发生率,以死亡为竞争风险。
主要发现
- 12个月大ICH累积发生率DOAC组为5.1%,LMWH组为11.1%(HR 0.45;95%CI 0.09-2.21)。
- 将抗凝作为时间变化协变量分析,任何ICH风险在DOAC与LMWH组间无差异(HR 0.98;95%CI 0.28-3.40)。
- PANWARDS评分与ICH风险无关。
关键数值与推荐
- 大ICH定义为自发性、体积≥10 mL、有症状或需外科干预。
- 影像学由对拮抗剂类型不知情的神经放射科医生集中审阅。
- PANWARDS评分用于预测ICH并计算。
临床怎么用
- 脑转移患者因静脉血栓栓塞或房颤需抗凝时,DOAC与LMWH均可考虑,安全性相当。
- PANWARDS评分不宜用于此类患者ICH风险分层。
局限性
- 回顾性设计,样本量96例,事件数少,置信区间宽。
- 仅两中心,外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Direct oral anticoagulants (DOACs) are increasingly prescribed in treatment of cancer-associated thrombosis, but limited data exist regarding safety of DOACs in patients with brain metastases. We aimed to determine the incidence of intracranial hemorrhage (ICH) in patients with brain metastases receiving DOACs or low-molecular-weight heparin (LMWH) for venous thromboembolism or atrial fibrillation. An international 2-center retrospective cohort study was designed. Follow-up started on the first day of concomitant anticoagulation and brain tumor diagnosis. At least 2 brain imaging studies were mandated. The primary outcome was the cumulative incidence of any spontaneous ICH at 12-month follow-up with death as a competing risk. Major ICH was defined as spontaneous, ≥10 mL in volume, symptomatic, or requiring surgical intervention. Imaging studies were centrally reviewed by a neuroradiologist blinded for anticoagulant type. PANWARDS (platelets, albumin, no congestive heart failure, warfarin, age, race, diastolic blood pressure, stroke) score for prediction of ICH was calculated. We included 96 patients with brain metastases (41 DOAC, 55 LMWH). The 12-month cumulative incidence of major ICH was 5.1% in DOAC-treated patients and 11.1% in those treated with LMWH (hazard ratio [HR], 0.45; 95% confidence interval [CI], 0.09-2.21). When anticoagulation was analyzed as a time-varying covariate, the risk of any ICH did not differ between DOAC- and LMWH-treated patients (HR, 0.98; 95% CI, 0.28-3.40). PANWARDS score was not associated with ICH risk. This international 2-center study suggests comparable safety of LMWH and DOACs in patients with brain metastases.
引用
- Leader A, Hamulyák EN, Carney BJ, et al. Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases. Blood Adv. 2020. PMID: 33351124. doi:10.1182/bloodadvances.2020003238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。